Douleur et Analgésie

, Volume 28, Issue 1, pp 31–39 | Cite as

Fibromyalgie : où en est-on en 2015 ?

Article de Synthèse / Review Article

Résumé

La fibromyalgie fait beaucoup parler d’elle et suscite encore débats et controverses en 2015. Pourtant, il n’est plus question de remettre en cause ce syndrome facilement reconnaissable (même si le diagnostic est aussi posé avec excès). Le modèle biopsychosocial permet de comprendre et de prendre en charge de façon plus globale toutes les maladies chroniques et évite la mise en échec des patients et des soignants. La fibromyalgie est un syndrome fréquent qui touche surtout les femmes qui rapportent des douleurs chroniques, diffuses, musculaires, tendineuses et/ou articulaires. Ces douleurs sont associées à des céphalées de tension, des troubles fonctionnels intestinaux, des symptômes génitourinaires, des acouphènes, des douleurs de l’articulation temporomandibulaire, des paresthésies distales... On parle de troubles somatoformes, définis par des symptômes fonctionnels sans lésion tissulaire. Les critères diagnostiques de l’American College of Rheumatology (ACR 1990) se sont affinés en 2010–2011 et permettent désormais de mieux appréhender les symptômes dans leur globalité et leur sévérité. Les comorbidités émotionnelles et cognitives sont très fréquentes (troubles anxieux, dépression, catastrophisme, hypervigilance, manque de flexibilité, troubles de concentration et de mémoire...). La sensibilisation du système nerveux central est l’hypothèse physiopathologique la plus consensuelle. Les symptômes surviennent sur un terrain favorisant, apparaissent au décours de facteurs précipitants (éventuellement) et sont entretenus et/ou aggravés par des facteurs d’entretien. Différents traitements médicamenteux antalgiques classiques et psychotropes (antiépileptiques et antidépresseurs) ont montré leur efficacité. Des recommandations internationales actualisées sont disponibles. Elles font consensus sur la prise en charge qui doit être multimodale et faire appel à des traitements médicamenteux d’action centrale, associés à des approches psychophysiques et éducatives. L’éducation des patients, comme pour toute pathologie chronique, est donc indispensable.

Mots clés

Fibromyalgie Reconnaissance médicale Dépistage Diagnostic Évaluation Prise en charge multimodale et multidisciplinaire 

Fibromyalgia: Where are we in 2015?

Abstract

Fibromyalgia is a heavily discussed topic and will continue to be at the centre of debates and disputes in 2015. Nevertheless, it is no longer a matter of questioning this often easily recognisable syndrome (even if the diagnosis is also over-used). The biopsychosocial model enables greater overall understanding and management of chronic conditions, and minimises failures when it comes to patients and care providers. Fibromyalgia is a common condition that mainly effects women, who report having chronic, diffuse muscular, tendon and/or joint pain. This pain is associated with tension headaches, bowel function issues, genitourinary symptoms, tinnitus, temporomandibular joint pain and distal paresthesia, etc. The term somatic symptom disorder is used, which is defined as functional symptoms without any tissue lesions. The American College of Rheumatology (ACR 1990) diagnostic criteria were updated in 2010–2011, which now enables symptoms of this condition to be better understood, both in terms of scope and their severity. Emotional and cognitive comorbidities are very common (anxiety issues, depression, feeling of impending disaster, hypervigilance, lack of flexibility and concentration and memory issues). Sensitization of the nervous system is the most favoured pathophysiological hypothesis for what causes the condition. Symptoms occur when it is favourable, are more likely if there are precipitating factors (possibly) and are sustained and/or worsened by maintenance factors. Different classic and psychoactive (anticonvulsants and antidepressants) pain relief medicines have shown to be effective. Updated international guidelines are available. They provide a consensus on care, which should be multimodal and use centrally active medicinal treatments, combined with psycho-physical and educational approaches. Educating patients, as with all chronic conditions, is undoubtedly fundamental.

Keywords

Fibromyalgia Medical understanding Screening Diagnosis Evaluation Multimodal and multidisciplinary management 

Références

  1. 1.
    Branco J, Zachrisson O, Perrot S, et al (2010) European multicenter randomised double-blind placebo controlled trial of milnacipran in the treatment of fibromyalgia. J Rheumatol 37:851–9CrossRefPubMedGoogle Scholar
  2. 2.
    Perrot S, Vicaut E, Servant D, Ravaud P (2011) Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: the DEFI study (Determination of Epidemiology of FIbromyalgia). BMC Musculoskelet Disord 12:224CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Clauw D (2014) Fibromyalgia. A clinical review. JAMA 311:1547–55Google Scholar
  4. 4.
    Vincent A, Lahr B, Wolfe F, et al (2013) Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) 65:786–92CrossRefGoogle Scholar
  5. 5.
    Arnold L, Clauw D, McCarberg B, Fibro Collaborative (2011) Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc 86:457–64CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Annemans L, Le Lay K, Taieb C (2009) Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 27:547–59CrossRefPubMedGoogle Scholar
  7. 7.
    Perrot S, Bouhassira D, Fermanian J, Cercle d’étude de la douleur en rhumatologie (2010) Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain 150:250–6CrossRefPubMedGoogle Scholar
  8. 8.
    Fitzcharles M, Ste-Marie P, Goldenberg D, et al (2013) National fibromyalgia guideline advisory panel 2012: canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 18:119–26PubMedCentralPubMedGoogle Scholar
  9. 9.
    Laroche F (2014) Fibromyalgie. EMC (15-916-A-10) 9:1–8Google Scholar
  10. 10.
    Wolfe F, Smythe HA, Yunus MB, et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Commitee. Arthritis Rheum 33:160–72CrossRefPubMedGoogle Scholar
  11. 11.
    Wolfe F, Clauw D, Fitzcharles M, et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38:1113–22CrossRefPubMedGoogle Scholar
  12. 12.
    Wolfe F, Clauw D, Fitzcharles M, et al (2010) The ACR preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Research 62:600–10CrossRefPubMedGoogle Scholar
  13. 13.
    Gupta A, Silman AJ, Ray D, et al (2007) The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population based-study. Rheumatology 46:666–71CrossRefPubMedGoogle Scholar
  14. 14.
    Häuser W (2013) Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain 154:1216–23CrossRefPubMedGoogle Scholar
  15. 15.
    Jones G, Power C, Macfarlane G (2009) Adverse events in childwood and chronic widespread pain in adult life: results from the 1958 British Birth Cohort Study. Pain 143:92–6CrossRefPubMedGoogle Scholar
  16. 16.
    Burckhardt C, Goldenberg D, Crofford L, et al (2005) Fibromyalgia syndrome pain management guideline panel 2002–2005, Guideline for the management of fibromyalgia syndrome pain in adults and children. APS clinical practice guidelines seriesGoogle Scholar
  17. 17.
    Perrot S, Dumont D, Guillemin F, et al (2003) For the french group of quality of life research. Quality of life in women with fibromyalgia syndrome: validation of the QIF, the French version of the fibromyalgia impact questionnaire. J Rheumatol 30:1054–59PubMedGoogle Scholar
  18. 18.
    Wolfe F, Brahler E, Hinz A, et al (2013) Fibromyalgia prevalence, somatic symptom reporting and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res 65:777–85CrossRefGoogle Scholar
  19. 19.
    Arnold L, Hudson J, Hess E, et al (2004) Family study of fibromyalgia. Arthritis Rheum 50:944–52CrossRefPubMedGoogle Scholar
  20. 20.
    Holliday K, McBeth J (2001) Recent advances in the understanding of genetic susceptibility to chronic pain and somatic symptoms. Curr Rheumatol Rep 13:521–7CrossRefGoogle Scholar
  21. 21.
    Mundal I, Grawe R, Bjorngaard J, et al (2014) Psychosocial factors and risk of chronic widespread pain: an 1 year follow-up study — The HUNT study. Pain 155:1555–61CrossRefPubMedGoogle Scholar
  22. 22.
    Woolf C (2011) Central sensitization implications for the diagnosis and treatment of pain. Pain 152:S2–S15CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Gracely RH, Petzke F, Wolf JM, Clauw DJ (2002) Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46:1333–43CrossRefPubMedGoogle Scholar
  24. 24.
    Ichesco E, Schmidt-Wilcke T, Bhaavsar R, et al (2014) Altered resting state connectivity of the insular cortex in individuals with fibromyalgia. J Pain 15:815–26CrossRefPubMedGoogle Scholar
  25. 25.
    Burgmer M, Gaubitz M, Konrad C, et al (2009) Decreased gray matter volumes in the cingular-frontal cortex and the amygdale in patients in fibromyalgia. Psychosom Med 71:566–73CrossRefPubMedGoogle Scholar
  26. 26.
    Ramirez F, Martinez L, Vargas A, et al (2014) Small fiber neuropathy in women with fibromyalgia. A clinical-pathological correlation using confocal corneal biomicroscopy. ACR Congress 2014; Abst 894Google Scholar
  27. 27.
    Adler GK, Geenen R (2005) Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin N Am 31:187–202CrossRefGoogle Scholar
  28. 28.
    Nicholl B, Holliday K, Macfarlane G, et al (2011) Association of HTR2A polymorphism with chronic widespread pain and the extent of musculoskeletal pain. Arthritis Rheum 63:810–8CrossRefPubMedGoogle Scholar
  29. 29.
    McLean SA, Williams DA, Harris RE, et al (2005) Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 52:3660–9CrossRefPubMedGoogle Scholar
  30. 30.
    Cordero M, De Miguel M, Moreno Fernánde A, et al (2010) Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 12:R17CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Gloth FM, Lindsay JM, Zelesnick LB, Greenough WB (1991) Can vitamin D deficiency produce an unusual pain syndrome ? Arch Intern Med 151:1662–4CrossRefPubMedGoogle Scholar
  32. 32.
    Janicki PK, Schuler G, Francis D, et al (2006) A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 103:1011–17CrossRefPubMedGoogle Scholar
  33. 33.
    Hassett A, Clauw D, Harris R, et al (2012) Pain is associated with short leukocyte telomere lengh in women with fibromyalgia. J Pain 13:959–69CrossRefPubMedGoogle Scholar
  34. 34.
    Bennett RM, Kamin M, Karim R, Rosenthal N (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double blind, randomized, placebo-controlled study. Am J Med 114:537–45CrossRefPubMedGoogle Scholar
  35. 35.
    Carville SF, Arendt-Nielsen S, Bliddal H, et al (2007) EULAR evidence-based recommandations for the management of fibromyalgia syndrome. Ann Rheum Dis 67:536–41CrossRefPubMedGoogle Scholar
  36. 36.
    Häuser W, Thieme K, Turk D (2010) Guidelines on the management of fibromyalgia syndrome — a systematic review. Eur J Pain 14:5–10CrossRefPubMedGoogle Scholar
  37. 37.
    Häuser W, Bernardy K, Uceyler N, et al (2009) Treatment of fibromyalgia syndrome with antidepressants — a metaanalysis. JAMA 301:198–209CrossRefPubMedGoogle Scholar
  38. 38.
    Moore R (2012) Amitriptiline for neuropathic pain in fibromyalgia in adults. Cochrane Database Syst Rev 12:CD008242PubMedGoogle Scholar
  39. 39.
    Crofford LJ, Rowbotham MC, Mease PJ (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:1264–73CrossRefPubMedGoogle Scholar
  40. 40.
    Häuser W, Bernardy K, Uçeyler N, et al (2009) Treatment of fibromyalgia syndrome with gabapentin and pregabalin — a metaanalysis of randomised controlled trials. Pain 145:69–81CrossRefPubMedGoogle Scholar
  41. 41.
    Holman AJ, Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52:2495–505CrossRefPubMedGoogle Scholar
  42. 42.
    Vergne-Salle P, Dufauret-Lombard C, Bonnet C (2010) A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain 15:509–14CrossRefPubMedGoogle Scholar
  43. 43.
    Younger J, Noor N, McCue R, et al (2013) Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 65:529–38CrossRefPubMedGoogle Scholar
  44. 44.
    Bernardy K, Füber N, Köllner V, et al (2010) Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome — a systematic review and meta-analysis of randomized controlled trials. J Rheumatol 37:1991–205CrossRefPubMedGoogle Scholar
  45. 45.
    Glombiewski J, Sawyer A, Gutermann J, et al (2010) Psychological treatments for fibromyalgia: a meta-analysis. Pain 151:280–95CrossRefPubMedGoogle Scholar
  46. 46.
    Ablin J, Fitzcharles MA, Buskila D (2013) Treatment of fibromyalgia syndrome: recommandations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med (eCAM) ID 485272, 7 pagesGoogle Scholar
  47. 47.
    Luciano J, Guallar J, Aguado J, et al (2014) Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-months randomized controlled trial (EFFIGACT study). Pain 155:693–702CrossRefPubMedGoogle Scholar
  48. 48.
    Picard P, Jusseaume C, Boutet M, et al (2013) Hypnosis for management of fibromyalgia. Int Clin Exp Hypn 61:111–23CrossRefGoogle Scholar
  49. 49.
    Busch A, Webber C, Richards R, et al (2013) Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev 12: CD010884PubMedGoogle Scholar
  50. 50.
    Mist S, Firestone K, Jones D (2013) Complementary and alternative exercise for fibromyalgia: a meta-analysis. J Pain Res 6:247–60CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Naumann J, Sadaghiani C (2014) Therapeutic benefit of balneotherapy and hydrotherapy in the management of fibromyalgia syndrome: a qualitative systematic review and meta-analysis of randomized controlled trials. Arthritis Res Ther 16:R141CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Deare J, Zheng Z, Xue C, et al (2013) Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev 5:CD007070PubMedCentralPubMedGoogle Scholar
  53. 53.
    Hargrove J, Benett R, Simons D, et al (2012) A randomized placebo controlled study of non-invasive cortical electrostimulation in the treatment of fibromyalgia. Pain Med 13:115–24CrossRefPubMedGoogle Scholar
  54. 54.
    Marlow N, Bonilha H, Short E (2013) Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. Pain Pract 13:131–45CrossRefPubMedGoogle Scholar
  55. 55.
    Mhalla A, Baudic S, Ciampi de Andrade D, et al (2011) Long term maintenance of the analgesic effects of transcranial magnetic stimulation in fibromyalgia. Pain 152:1478–85CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2015

Authors and Affiliations

  1. 1.UMRS 938, unité Inserm, centre d’évaluation et de traitement de la douleurhôpital Saint-AntoineParisFrance
  2. 2.Cercle d’étude de la douleur en rhumatologie (CEDR)section douleur de la SFRParisFrance
  3. 3.Centre d’évaluation et de traitement de la douleurhôpital Saint-AntoineParisFrance

Personalised recommendations